Endovastec(SH:688016) Sou Hu Cai Jing·2025-04-16 12:22Core Viewpoint - The company, Shanghai MicroPort CardioFlow Medtech Co., Ltd., is experiencing a decline in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential undervaluation in the context of its financial performance and market position [1][2]. Company Overview - The main business of the company includes the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels [2]. - Key products include thoracic aortic stent graft systems, abdominal aortic stent graft systems, and various types of stents and balloons [2]. - The company has received several accolades, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2]. Financial Performance - For the fiscal year 2024, the company reported a revenue of 1.206 billion yuan, representing a year-on-year increase of 1.61% [2]. - The net profit for the same period was 502 million yuan, reflecting a year-on-year growth of 1.96% [2]. - The gross profit margin stands at 73.01%, indicating strong profitability [2]. Market Position - As of the latest data, the company's rolling PE ratio is 21.19, significantly lower than the industry average of 45.94 and the median of 29.64, positioning it at 47th among its peers [1][3]. - The total market capitalization of the company is approximately 10.639 billion yuan [1]. Institutional Holdings - A total of 259 institutions hold shares in the company, with 253 being funds, 4 others, 1 brokerage, and 1 social security fund, amounting to a total holding of 73.239 million shares valued at 8.045 billion yuan [1].